| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R Larisch, K W Schulte, H Vosberg, T Ruzicka, H W Müller-Gärtne. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 39. issue 6. 1998-07-02. PMID:9627332. |
this has been attributed to specific dopamine d2 receptor binding on melanoma cells because melanocytes and dopaminergic neurons share the same ectodermal origin and are both able to produce melanin. |
1998-07-02 |
2023-08-12 |
Not clear |
| J Behrends, K Prank, E Dogu, G Braban. Central nervous system control of thyrotropin secretion during sleep and wakefulness. Hormone research. vol 49. issue 3-4. 1998-06-30. PMID:9550121. |
in contrast, blockade of dopaminergic tone by metoclopramide infusion when circulating tsh levels are low during the afternoon hours increase tsh pulse amplitude to levels comparable to the nightly tsh surge suggesting a physiological dampening of tsh pulse amplitude by dopamine during the daytime. |
1998-06-30 |
2023-08-12 |
Not clear |
| B S Jeon, J M Jeong, S S Park, J M Kim, Y S Chang, H C Song, K M Kim, K Y Yoon, M C Lee, S B Le. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Annals of neurology. vol 43. issue 6. 1998-06-25. PMID:9629849. |
the dopamine transporter (dat) is a protein in the dopaminergic nerve terminals. |
1998-06-25 |
2023-08-12 |
human |
| W C Koller, M G Rued. Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology. vol 50. issue 6 Suppl 6. 1998-06-25. PMID:9633680. |
although the exact site of decarboxylation of exogenous levodopa to dopamine in the brain is unknown, most striatal aadc is located in nigrostriatal dopaminergic nerve terminals. |
1998-06-25 |
2023-08-12 |
Not clear |
| W Poew. Adjuncts to levodopa therapy: dopamine agonists. Neurology. vol 50. issue 6 Suppl 6. 1998-06-25. PMID:9633683. |
continuous dopaminergic stimulation via subcutaneous dopamine agonist infusions is being investigated as a way to control levodopa-associated peak-dose dyskinesias. |
1998-06-25 |
2023-08-12 |
Not clear |
| P G Jenner, M F Bri. Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology. vol 50. issue 6 Suppl 6. 1998-06-25. PMID:9633686. |
there is no clinical evidence to suggest that levodopa has adverse effects on dopamine cells in normal humans or on the viability of remaining dopaminergic cells in patients with pd. |
1998-06-25 |
2023-08-12 |
rat |
| B Caronti, C Calderaro, F Passarelli, G Palladini, F E Pontier. Dopamine receptor mRNAs in the rat lymphocytes. Life sciences. vol 62. issue 21. 1998-06-18. PMID:9619840. |
these results provide further evidence for the interaction of dopamine systems and the immune system, and suggest to further investigate whether the immunosuppressive actions of dopamine and dopaminergic drugs might depend on a direct interaction with dopamine receptors on the lymphocyte membrane. |
1998-06-18 |
2023-08-12 |
rat |
| T Hashitani, K Mizukawa, M Kumazaki, H Nishin. Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts. Neuroscience research. vol 30. issue 1. 1998-06-16. PMID:9572579. |
dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts. |
1998-06-16 |
2023-08-12 |
rat |
| T Okada, S Shimada, K Sato, Y Kotake, H Kawai, S Ohta, M Tohyama, T Nishimur. Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells. Neuroscience research. vol 30. issue 1. 1998-06-16. PMID:9572583. |
since thp is considered to be synthesized from dopamine, it may affect dopaminergic neurons through the reuptake system, i.e. |
1998-06-16 |
2023-08-12 |
rat |
| M Watanabe, R Nonaka, Y Hagino, Y Kodam. Effects of prenatal methylazoxymethanol treatment on striatal dopaminergic systems in rat brain. Neuroscience research. vol 30. issue 2. 1998-06-16. PMID:9579647. |
to further examine the effects of prenatal methylazoxymethanol (mam) treatment on striatal dopaminergic systems, the status of presynaptic dopamine transporters was examined by quantitative autoradiography of [3h]gbr 12935 binding. |
1998-06-16 |
2023-08-12 |
rat |
| M Naumann, W Pirker, K Reiners, K W Lange, G Becker, T Brück. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Movement disorders : official journal of the Movement Disorder Society. vol 13. issue 2. 1998-06-15. PMID:9539347. |
[123i] epidepride is a new highly affine marker of d2 receptors, and [123i] beta-cit binds to dopamine transporters on dopaminergic nerve endings. |
1998-06-15 |
2023-08-12 |
human |
| M Matsumoto, M Yoshioka, H Togashi, K Mori, K Ueno, H Sait. Effects of idazoxan on dopamine release in the prefrontal cortex of freely moving rats. European journal of pharmacology. vol 343. issue 2-3. 1998-06-09. PMID:9570464. |
to clarify the involvement of dopaminergic neuronal systems in anxiety or fear, the present study was undertaken to elucidate the effect of an anxiogenic agent, idazoxan, a selective alpha2-adrenoceptor antagonist, on dopamine release from the rat prefrontal cortex by use of in vivo microdialysis. |
1998-06-09 |
2023-08-12 |
rat |
| J L Martín-Calderón, R M Muñoz, M A Villanúa, I del Arco, J L Moreno, F R de Fonseca, M Navarr. Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. European journal of pharmacology. vol 344. issue 1. 1998-06-09. PMID:9580419. |
this dose induced activation of tubero-infundibular dopaminergic neurons, as reflected by the decrease in hypothalamic contents of dopamine in both males and females in the afternoon of the proestrus phase. |
1998-06-09 |
2023-08-12 |
rat |
| T N Chas. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. vol 50. issue 5 Suppl 5. 1998-06-09. PMID:9591518. |
levodopa, the standard of care for the treatment of pd, acts after its conversion to dopamine by restoring striatal dopaminergic transmission. |
1998-06-09 |
2023-08-12 |
Not clear |
| C S Myers, M Witten, Y L Yu, G C Wagne. L-DOPA exacerbates amphetamine-induced dopamine depletion. Molecular and chemical neuropathology. vol 33. issue 2. 1998-06-08. PMID:9565967. |
this enhanced toxicity may be consequent to increased dopamine turnover following l-dopa (360 vs 231%), a situation akin to that observed in compromised dopaminergic nigrostriatal systems of parkinsonian patients. |
1998-06-08 |
2023-08-12 |
mouse |
| J W Błaszczy. Motor deficiency in Parkinson's disease. Acta neurobiologiae experimentalis. vol 58. issue 1. 1998-06-08. PMID:9583191. |
the pathological process behind the motor disabilities of parkinsonism is a progressive degeneration of dopaminergic neurons of the substantia nigra, that results in dopamine depletion in the striatum. |
1998-06-08 |
2023-08-12 |
Not clear |
| J L Do Nascimento, R C Kubrusly, R A Reis, M C De Mello, F G De Mell. Atypical effect of dopamine in modulating the functional inhibition of NMDA receptors of cultured retina cells. European journal of pharmacology. vol 343. issue 1. 1998-06-04. PMID:9551720. |
our results suggest that dopamine and (+)-skf 38393 inhibit the glutamate and nmda-evoked [3h]gaba release through mechanisms that seem not to involve known dopaminergic receptor systems. |
1998-06-04 |
2023-08-12 |
Not clear |
| R J Flietstra, B Levan. Comparison of D2 and D3 dopamine receptor affinity of dopaminergic compounds in rat brain. Life sciences. vol 62. issue 20. 1998-06-04. PMID:9600324. |
this study used quantitative autoradiography to simultaneously evaluate the relative affinities of dopaminergic compounds for dopamine d2 and d3 receptors in rat brain. |
1998-06-04 |
2023-08-12 |
rat |
| I Singer, M Epstei. Potential of dopamine A-1 agonists in the management of acute renal failure. American journal of kidney diseases : the official journal of the National Kidney Foundation. vol 31. issue 5. 1998-06-03. PMID:9590183. |
to date, most therapeutic studies have investigated the effects of diuretics (eg, mannitol, furosemide), vasoactive agents (calcium channel blockers, atrial natriuretic peptide), or dopamine (a nonselective dopaminergic agent [daa]) in one or more phases of arf. |
1998-06-03 |
2023-08-12 |
human |
| I Singer, M Epstei. Potential of dopamine A-1 agonists in the management of acute renal failure. American journal of kidney diseases : the official journal of the National Kidney Foundation. vol 31. issue 5. 1998-06-03. PMID:9590183. |
the undesirable side effects of high doses of dopamine and the inconclusive results using low doses (ie, "renal doses") of dopamine (a nonselective daa) have prompted consideration of the use of more selective dopaminergic agonists for the prophylaxis and treatment of arf. |
1998-06-03 |
2023-08-12 |
human |